ForecastQ
PortfoliosScreenerAbout

DMAC

Portfolios > Smallcap > DMAC

DMAC

DiaMedica Therapeutics Inc.

Company Information

SectorHealthcare
IndustryBiotechnology
Market Cap$0.51B
Analysts Rating2.0/5

Recommendation Details

PortfolioSmallcap
DateNov 12, 2026
ForecastQ Daily Probabilities
40.6%
51.8%
29.5%

Company Description

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.

Recent News & Events

Near-term catalysts center on the Q3 2026 earnings release tonight (Nov 12) and business update call (Nov 13), plus a Nov 24 KOL webinar with new FGR cohort data; both are modest binary events for a pre-revenue biotech, with the major ReMEDy2 interim analysis not due until Q1 2027.

NEUTRALNov 12, 2026
Earnings Report

Q3 2026 results after close Nov 12, call Nov 13

DiaMedica will release Q3 2026 financial results after market close on Nov 12, 2026, with a business update call on Nov 13 at 8:00 AM ET. Consensus expects a net loss of about -$0.21 per share with no product revenue; focus will be on R&D spend trends, cash balance (~$43.5M at Q2) and runway guidance into 2027, plus any ReMEDy2 timeline commentary. Quarterly prints have historically produced contained moves for this pre-revenue biotech, so impact is likely modest unless cash burn or timelines surprise.

DiaMedica Press Release
POSITIVENov 24, 2026
Clinical Data Event / KOL Webinar

Nov 24 KOL webinar to include new FGR cohort data

DiaMedica rescheduled its FGR key opinion leader webinar to Nov 24, 2026, expanding it to include preliminary interim topline results from the second cohort of the investigator-sponsored Phase 2 early-onset FGR trial alongside first-cohort data. Positive safety/efficacy signals could support the preeclampsia/FGR franchise narrative and lift shares, while weak or ambiguous data could weigh on sentiment.

DiaMedica Press Release
POSITIVEOct 22, 2026
Clinical Trial Milestone

ReMEDy2 reaches 200-patient interim analysis threshold

DiaMedica announced enrollment of the 200th patient in the pivotal Phase 2/3 ReMEDy2 AIS trial, triggering the prespecified DSMB interim analysis for sample size re-estimation or futility. Results are expected in Q1 2027, so this is a de-risking/enrollment-progress signal rather than an immediate catalyst, but it keeps the key binary event on schedule and supports the clinical narrative.

DiaMedica Press Release

ForecastQ

Quantitative stocks signals powered by AI

Portfolios·Screener·About

The information provided is for educational purposes only and should not be considered financial advice. Past performance is not indicative of future results. ForecastQ is a research platform, a living documentation of an engineering experiment. We are not financial advisors.

© ForecastQ. All rights reserved.